These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 36715306)

  • 41. p53 Function Is Compromised by Inhibitor 2 of Phosphatase 2A in Sonic Hedgehog Medulloblastoma.
    Wei Y; Maximov V; Morrissy SA; Taylor MD; Pallas DC; Kenney AM
    Mol Cancer Res; 2019 Jan; 17(1):186-198. PubMed ID: 30224541
    [TBL] [Abstract][Full Text] [Related]  

  • 42. SHH inhibitors for the treatment of medulloblastoma.
    Samkari A; White J; Packer R
    Expert Rev Neurother; 2015; 15(7):763-70. PubMed ID: 26027634
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma.
    Pak E; MacKenzie EL; Zhao X; Pazyra-Murphy MF; Park PMC; Wu L; Shaw DL; Addleson EC; Cayer SS; Lopez BG; Agar NYR; Rubin LL; Qi J; Merk DJ; Segal RA
    Neuro Oncol; 2019 Sep; 21(9):1150-1163. PubMed ID: 31111916
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
    Li Y; Song Q; Day BW
    Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788
    [TBL] [Abstract][Full Text] [Related]  

  • 45. SHH desmoplastic/nodular medulloblastoma and Gorlin syndrome in the setting of Down syndrome: case report, molecular profiling, and review of the literature.
    Mangum R; Varga E; Boué DR; Capper D; Benesch M; Leonard J; Osorio DS; Pierson CR; Zumberge N; Sahm F; Schrimpf D; Pfister SM; Finlay JL
    Childs Nerv Syst; 2016 Dec; 32(12):2439-2446. PubMed ID: 27444290
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biological and clinical heterogeneity of MYCN-amplified medulloblastoma.
    Korshunov A; Remke M; Kool M; Hielscher T; Northcott PA; Williamson D; Pfaff E; Witt H; Jones DT; Ryzhova M; Cho YJ; Wittmann A; Benner A; Weiss WA; von Deimling A; Scheurlen W; Kulozik AE; Clifford SC; Peter Collins V; Westermann F; Taylor MD; Lichter P; Pfister SM
    Acta Neuropathol; 2012 Apr; 123(4):515-27. PubMed ID: 22160402
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outcomes of a radiation sparing approach in medulloblastoma by subgroup in young children: an institutional review.
    Ronsley R; Triscott J; Stanek J; Rassekh SR; Lum A; Cheng S; Goddard K; McConnell D; Strahlendorf C; Singhal A; Finlay JL; Yip S; Dunham C; Hukin J
    Childs Nerv Syst; 2023 Aug; 39(8):2095-2104. PubMed ID: 37022464
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Medulloblastoma in Adults: Cytogenetic Phenotypes Identify Prognostic Subgroups.
    Goschzik T; Zur Muehlen A; Doerner E; Waha A; Friedrich C; Hau P; Pietsch T
    J Neuropathol Exp Neurol; 2021 Apr; 80(5):419-430. PubMed ID: 33870422
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression of GNAS, TP53, and PTEN Improves the Patient Prognostication in Sonic Hedgehog (SHH) Medulloblastoma Subgroup.
    da Silva LS; Mançano BM; de Paula FE; Dos Reis MB; de Almeida GC; Matsushita M; Junior CA; Evangelista AF; Saggioro F; Serafini LN; Stavale JN; Malheiros SMF; Lima M; Hajj GNM; de Lima MA; Taylor MD; Leal LF; Reis RM
    J Mol Diagn; 2020 Jul; 22(7):957-966. PubMed ID: 32380172
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic significance of molecular subgroups of medulloblastoma in young children receiving irradiation-sparing regimens.
    Yeo KK; Margol AS; Kennedy RJ; Hung L; Robison NJ; Dhall G; Asgharzadeh S
    J Neurooncol; 2019 Nov; 145(2):375-383. PubMed ID: 31621042
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intraventricular SHH inhibition proves efficient in SHH medulloblastoma mouse model and prevents systemic side effects.
    Kresbach C; Holst L; Schoof M; Leven T; Göbel C; Neyazi S; Tischendorf J; Loose C; Wrzeszcz A; Yorgan T; Rutkowski S; Schüller U
    Neuro Oncol; 2024 Apr; 26(4):609-622. PubMed ID: 37767814
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations.
    Thompson MC; Fuller C; Hogg TL; Dalton J; Finkelstein D; Lau CC; Chintagumpala M; Adesina A; Ashley DM; Kellie SJ; Taylor MD; Curran T; Gajjar A; Gilbertson RJ
    J Clin Oncol; 2006 Apr; 24(12):1924-31. PubMed ID: 16567768
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of SHH pathway mechanisms by arsenic trioxide in pediatric medulloblastomas: a comprehensive literature review.
    Klinger PH; Andrade AF; Delsin LE; Queiroz RG; Scrideli CA; Tone LG; Valera ET
    Genet Mol Res; 2017 Feb; 16(1):. PubMed ID: 28218785
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A CTNNB1-altered medulloblastoma shows the immunophenotypic, DNA methylation and transcriptomic profiles of SHH-activated, and not WNT-activated, medulloblastoma.
    Chiang J; Moreira DC; Pytel NJ; Liu YC; Blackburn PR; Shi Z; Cardenas M; Wheeler DA; Furtado LV
    Neuropathol Appl Neurobiol; 2022 Aug; 48(5):e12815. PubMed ID: 35320876
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunohistochemical and nanoString-Based Subgrouping of Clinical Medulloblastoma Samples.
    D'Arcy CE; Nobre LF; Arnaldo A; Ramaswamy V; Taylor MD; Naz-Hazrati L; Hawkins CE
    J Neuropathol Exp Neurol; 2020 Apr; 79(4):437-447. PubMed ID: 32053195
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of early childhood medulloblastoma by postoperative chemotherapy and deferred radiotherapy.
    Rutkowski S; Gerber NU; von Hoff K; Gnekow A; Bode U; Graf N; Berthold F; Henze G; Wolff JE; Warmuth-Metz M; Soerensen N; Emser A; Ottensmeier H; Deinlein F; Schlegel PG; Kortmann RD; Pietsch T; Kuehl J;
    Neuro Oncol; 2009 Apr; 11(2):201-10. PubMed ID: 18818397
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups.
    Ellison DW; Dalton J; Kocak M; Nicholson SL; Fraga C; Neale G; Kenney AM; Brat DJ; Perry A; Yong WH; Taylor RE; Bailey S; Clifford SC; Gilbertson RJ
    Acta Neuropathol; 2011 Mar; 121(3):381-96. PubMed ID: 21267586
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pediatric Patients With SHH Medulloblastoma Fail Differently as Compared With Adults: Possible Implications for Treatment Modifications.
    Dasgupta A; Gupta T; Sridhar E; Shirsat N; Krishnatry R; Goda JS; Chinnaswamy G; Jalali R
    J Pediatr Hematol Oncol; 2019 Nov; 41(8):e499-e505. PubMed ID: 30973484
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preponderance of sonic hedgehog pathway activation characterizes adult medulloblastoma.
    Al-Halabi H; Nantel A; Klekner A; Guiot MC; Albrecht S; Hauser P; Garami M; Bognar L; Kavan P; Gerges N; Shirinian M; Roberge D; Muanza T; Jabado N
    Acta Neuropathol; 2011 Feb; 121(2):229-39. PubMed ID: 21107850
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nomograms based on preoperative multiparametric magnetic resonance imaging for prediction of molecular subgrouping in medulloblastoma: results from a radiogenomics study of 111 patients.
    Dasgupta A; Gupta T; Pungavkar S; Shirsat N; Epari S; Chinnaswamy G; Mahajan A; Janu A; Moiyadi A; Kannan S; Krishnatry R; Sastri GJ; Jalali R
    Neuro Oncol; 2019 Jan; 21(1):115-124. PubMed ID: 29846693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.